This study examined the potential of TIM-3 as a negative differential biomarker for B-ALL, suggesting that significantly lower levels of TIM-3 gene expression could be used as a negative biomarker, especially in the relapsed/refractory phase. This evidence concerns the gene HAVCR2 and acute lymphoblastic leukemia.